A longitudinal study of pain variability and its correlates in ambulatory patients with advanced stage cancer

Cancer

Volumn 118, Issue 24, 2012, Pages 6278-6286

  Zhu, Junya ^a,b   Davis, Roger B ^c   Stuver, Sherri O ^a   Berry, Donna L ^a   Block, Susan ^a   Weeks, Jane C ^a   Weingart, Saul N ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRANDEIS UNIVERSITY   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

advanced cancer; electronic medical record; longitudinal study; pain intensity; pain variability; tumor registry

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER PAIN; CANCER STAGING; DIGESTIVE SYSTEM CANCER; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEAD AND NECK CANCER; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OVERALL SURVIVAL; PAIN ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SOLID TUMOR; THORAX CANCER; UROGENITAL TRACT CANCER;

ADOLESCENT; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PAIN; PAIN MEASUREMENT; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 84870713703     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27673     Document Type: Article

References (50)

1. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J,. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007; 18: 1437-1449.
2. Wilson KG, Chochinov HM, Allard P, et al. Prevalence and correlates of pain in the Canadian National Palliative Care Survey. Pain Res Manag. 2009; 14: 365-370.
3. Mercadante S,. Management of cancer pain. Intern Emerg Med. 2010; 5: S31-S35.
4. Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A,. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage. 2007; 34: 94-104.
5. Portenoy RK,. Treatment of cancer pain. Lancet. 2011; 377: 2236-2247.
6. Frampton CL, Hughes-Webb P,. The measurement of pain. Clin Oncol (R Coll Radiol). 2011; 23: 381-386.
7. Paice JA,. Chronic treatment-related pain in cancer survivors. Pain. 2011; 152: S84-S89.
8. Lasheen W, Walsh D, Hauser K, Gutgsell T, Karafa MT,. Symptom variability during repeated measurement among hospice patients with advanced cancer. Am J Hosp Palliat Care. 2009; 26: 368-375.
9. Deandrea S, Montanari M, Moja L, Apolone G,. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol. 2008; 19: 1985-1991.
10. Wang HL, Kroenke K, Wu J, Tu W, Theobald D, Rawl SM,. Cancer-related pain and disability: a longitudinal study. J Pain Symptom Manage. 2011; 42: 813-821.
11. Chaplin JM, Morton RP,. A prospective, longitudinal study of pain in head and neck cancer patients. Head Neck. 1999; 21: 531-537.
12. Butt Z, Wagner LI, Beaumont JL, et al. Longitudinal screening and management of fatigue, pain, and emotional distress associated with cancer therapy. Support Care Cancer. 2008; 16: 151-159.
13. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guideline in Oncology (NCCN Guidelines): Adult Cancer Pain. Version 2. Fort Washington, PA: National Comprehensive Cancer Network; 2011.
14. Fritz A, Percy C, Jack A, et al, eds. International Classification of Diseases for Oncology (ICD-O). 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
15. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002.
16. Gavaruzzi T, Carnaghi A, Lotto L, et al. Recalling pain experienced during a colonoscopy: pain expectation and variability. Br J Health Psychol. 2010; 15: 253-264.
17. Cole JM, Best BM, Pesce AJ,. Variability of transdermal fentanyl metabolism and excretion in pain patients. J Opioid Manag. 2010; 6: 29-39.
18. Harris RE, Williams DA, McLean SA, et al. Characterization and consequences of pain variability in individuals with fibromyalgia. Arthritis Rheum. 2005; 52: 3670-3674.
19. Valeberg BT, Rustøen T, Bjordal K, Hanestad BR, Paul S, Miaskowski C,. Self-reported prevalence, etiology, and characteristics of pain in oncology outpatients. Eur J Pain. 2008; 12: 582-590.
20. Dy S, M. Evidence-based approaches to pain in advanced cancer. Cancer J. 2010; 16: 500-506.
21. Montague L, Green CR,. Cancer and breakthrough pain's impact on a diverse population. Pain Med. 2009; 10: 549-561.
22. Green CR, Hart-Johnson T, Loeffler DR,. Cancer-related chronic pain: examining quality of life in diverse cancer survivors. Cancer. 2011; 117: 1994-2003.
23. Green CR, Montague L, Hart-Johnson TA,. Consistent and breakthrough pain in diverse advanced cancer patients: a longitudinal examination. J Pain Symptom Manage. 2009; 37: 831-847.
24. Castel LD, Saville BR, DePuy V, Godley PA, Hartmann KE, Abernethy AP,. Racial differences in pain during 1 year among women with metastatic breast cancer: a hazards analysis of interval-censored data. Cancer. 2008; 112: 162-170.
25. Anderson KO, Green CR, Payne R,. Racial and ethnic disparities in pain: causes and consequences of unequal care. J Pain. 2009; 10: 1187-1204.
26. Anderson KO, Mendoza TR, Valero V, et al. Minority cancer patients and their providers: pain management attitudes and practice. Cancer. 2000; 88: 1929-1938.
27. Cintron A, Morrison RS,. Pain and ethnicity in the United States: a systematic review. J Palliat Med. 2006; 9: 1454-1473.
28. Shavers VL, Bakos A, Sheppard VB,. Race, ethnicity, and pain among the US adult population. J Health Care Poor Underserved. 2010; 21: 177-220.
29. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994; 330: 592-596.
30. Burgess DJ, van Ryn M, Crowley-Matoka M, Malat J,. Understanding the provider contribution to race/ethnicity disparities in pain treatment: insights from dual process models of stereotyping. Pain Med. 2006; 7: 119-134.
31. Morrison RS, Wallenstein S, Natale DK, Senzel RS, Huang L,. "We don't carry that"-failure of pharmacies in predominantly nonwhite neighborhoods to stock opioid analgesics. N Engl J Med. 2000; 342: 1023-1026.
32. Pizzo PA, Clark NM,. Alleviating suffering 101-pain relief in the United States. N Engl J Med. 2012; 366: 197-199.
33. Flores G,. Language barriers to health care in the United States. N Engl J Med. 2006; 355: 229-231.
34. Institute of Medicine. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press; 2011.
35. Anderson KO, Richman SP, Hurley J, et al. Cancer pain management among underserved minority outpatients: perceived needs and barriers to optimal control. Cancer. 2002; 94: 2295-2304.
36. Bernabei R, Gambassi G, Lapane K, et al. Management of pain in elderly patients with cancer. JAMA. 1998; 279: 1877-1882.
37. Apolone G, Corli O, Caraceni A, et al. Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer. 2009; 100: 1566-1574.
38. Zucca AC, Boyes AW, Linden W, Girgis A,. All's well that ends well? Quality of life and physical symptom clusters in long-term cancer survivors across cancer types. J Pain Symptom Manage. 2012; 43: 720-731.
39. Gilbertson-White S, Aouizerat BE, Jahan T, Miaskowski C,. A review of the literature on multiple symptoms, their predictors, and associated outcomes in patients with advanced cancer. Palliat Support Care. 2011; 9: 81-102.
40. Greenwald HP, Bonica JJ, Bergner M,. The prevalence of pain in 4 cancers. Cancer. 1987; 60: 2563-2569.
41. Hammerlid E, Silander E, Hörnestam L, Sullivan M,. Health-related quality of life 3 years after diagnosis of head and neck cancer-a longitudinal study. Head Neck. 2001; 23: 113-125.
42. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M,. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX 327 study analysis. Clin Cancer Res. 2007; 13: 6396-6403.
43. Halabi S, Vogelzang NJ, Kornblith AB, et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol. 2008; 26: 2544-2549.
44. Carr B, I, Pujol L,. Pain at presentation and survival in hepatocellular carcinoma. J Pain. 2010; 11: 988-993.
45. Karvonen-Gutierrez CA, Ronis DL, Fowler KE, Terrell JE, Gruber SB, Duffy SA,. Quality of life scores predict survival among patients with head and neck cancer. J Clin Oncol. 2008; 26: 2754-2760.
46. Bottomley A, Coens C, Efficace F, et al. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol. 2007; 25: 5770-5776.
47. Herndon JE, Fleishman S, Kornblith AB, Kosty M, Green MR, Holland J,. Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer. 1999; 85: 333-340.
48. Scharpf J, Karnell LH, Christensen AJ, Funk GF,. The role of pain in head and neck cancer recurrence and survivorship. Arch Otolaryngol Head Neck Surg. 2009; 135: 789-794.
49. Montazeri A,. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008 [serial online]. Health Qual Life Outcomes. 2009; 7: 102.
50. Hughes A,. Poverty and palliative care in the US: issues facing the urban poor. Int J Palliat Nurs. 2005; 11: 6-13.